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Total Pancreatectomy with Islet Autologous
Transplantation: The Cure for Chronic Pancreatitis?
Samuel J. Kesseli1, Kerrington A. Smith, MD2 and Timothy B. Gardner, MD, MS3

Chronic pancreatitis (CP) is a debilitating disease that leads to varying degrees of pancreatic endocrine and exocrine dysfunction.
One of the most difficult symptoms of CP is severe abdominal pain, which is often challenging to control with available analgesics
and therapies. In the last decade, total pancreatectomy with autologous islet cell transplantation has emerged as a promising
treatment for the refractory pain of CP and is currently performed at approximately a dozen centers in the United States. While total
pancreatectomy is not a new procedure, the endocrine function-preserving autologous islet cell isolation and re-implantation have
made the prospect of total pancreatectomy more acceptable to patients and clinicians. This review will focus on the current status
of total pancreatectomy with autologous islet cell transplant including patient selection, technical considerations, and outcomes.
As the procedure is performed at an increasing number of centers, this review will highlight opportunities for quality improvement
and outcome optimization.
Clinical and Translational Gastroenterology (2015) 6, e73; doi:10.1038/ctg.2015.2; published online 29 January 2015

INTRODUCTION
Chronic pancreatitis (CP) is an often painful, debilitating
condition that accounts for more than 56,000 hospitalizations
annually in the United States.1 However, despite the more
widespread availability of diagnostic techniques that allow for
earlier identification of disease (such as endoscopic ultrasound and pancreatic function testing), the treatment of CP
has not changed appreciably in decades. Historically, treatment has involved medical management, drainage procedures, and in severe cases, total or subtotal pancreatectomy.
However, there is still no pharmacologic therapy that
specifically targets the inflammation and/or fibrosis, which
leads to the often recalcitrant pain of this disease, although
medication such as antioxidants and pancreatic enzyme
replacement therapy (PERT) are sometimes used to help
treat pain.2 In addition, although endoscopic and surgical
drainage can have value for patients with intraductal stones,
most patients with CP do not have lesions amenable to a
drainage procedure. Segmental pancreatic resection is limited
by the usual diffuse parenchymal involvement of CP and total
pancreatectomy leads to immediate lifetime dependence on
PERT and the development of type 3c diabetes with loss of
both insulin and the counter-regulatory hormone glucagon. As
a result, most patients with CP have few pharmacologic,
endoscopic, or surgical options and many eventually become
dependent on chronic opiate therapy to manage their pain
symptoms.2
As a means of reducing the risk of type 3c diabetes following
total pancreatectomy, in 1977 researchers at the University
of Minnesota School of Medicine pioneered the first Total
1

Pancreatectomy with Islet Autologous Transplant (TP-IAT) for
the treatment of CP.3 At that time, islet cell isolation techniques, which had been pursued to treat insulin-dependent
diabetes via allotransplant, yielded variable results and raised
uncertainty regarding the future efficacy of TP-IAT.4 Since
then, advances in isolation and purification have improved
islet transplant outcomes, and the practice of TP-IAT has
expanded.5–8 In the United States, there are currently
approximately 12 centers performing TP-IAT, with 1–2 centers
annually establishing programs; there is no available information on the worldwide use of this procedure.
However, despite significant progress, today TP-IAT remains
associated with variable outcomes in pain reduction and
endocrine functionality. Bearing in mind the risk and irreversible nature of pancreatic resection, the burden of lifelong
PERT, potential long-term complications such as gastrointestinal dysmotility, and the variable nature of the pain and islet cell
response, physicians must balance several considerations in
determining which patients are optimal candidates for TP-IAT.
Herein we provide recommendations for patient selection, a
detailed review of the procedure, and opportunities for further
quality improvement and implementation.
DETERMINING PATIENT ELIGIBILITY
Arguably, the most difficult aspect of the TP-IAT process is
determining which patients are likely to benefit from the
procedure. Given the risks, irreversible consequences, and
variable outcomes of TP-IAT, this determination can often be
challenging for the clinician. In fact, selecting patients for
an elective TP-IAT represents the penultimate in balancing
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Table 1 Recommendations from Pancreasfest in regard to indications, contraindications, evaluation, and timing for TP-IAT9

Guidance statement

Evidence
Grade of
levela recommendation

The primary indication for TP-IAT is to treat intractable pain in patients with impaired quality of life due to CP
or RAP in whom medical, endoscopic, or prior surgical therapy have failed

2a

B

TP-IAT should not be performed in patients with active alcoholism, active illicit substance abuse, or untreated/
uncontrolled psychiatric illness that could be expected to impair the patient’s ability to adhere to a complicated
medical management plan…Patients with poor support networks have a relative contraindication due to the
cost and complexity of managing diabetes and pancreatic enzyme replacement therapies

5

D

TP-IAT should not be performed in patients with specific medical conditions, including: c-peptide negative
diabetes, type 1 diabetes, portal vein thrombosis, portal hypertension, significant liver disease, high-risk
cardio-pulmonary disease, or known pancreatic cancer

5

D

There are no studies that specifically evaluate contraindications to this procedure. However, TP and TP-IAT
are major surgical procedures, with potential operative complications, a prolonged surgical recovery, and an
intensive post-operative regimen that includes management of diabetes mellitus and lifelong enzyme therapy
for pancreatic enzyme insufficiency

5

D

The severity, frequency, and duration of pain symptoms, narcotic requirements, disability/impaired quality of
life, residual islet function, rate of disease progression, and age of the patient should be considered in timing
of the procedure

5

D

Patients who meet the inclusion criteria (see above) and who are not excluded should be evaluated by a
multi-disciplinary team who will review alternative interventions, assess the likelihood of success in reducing
pain and preventing or minimizing diabetes, follow the patient through the procedure and provide guidance
for long-term care

5

D

Evaluation should include confirming that pancreatitis is the primary diagnosis, determining that the pain is
of pancreatic origin, monitoring the presence of diabetes, assessing beta-cell mass, and assessing the
patency of the portal venous system, evaluating for liver disease, and determining immunization status

5

D

CP, chronic pancreatitis; RAP, recurrent acute pancreatitis; TP-IAT, Total Pancreatectomy with Islet Autologous Transplant.
a
Methods of developing consensus based on the Grading of Recommendations, Assessment, Development, and Evaluation Grid.10

risk/reward. It is standard of care that a multidisciplinary team
comprising of at minimum a medical pancreatologist, pancreatic surgeon, and endocrinologist evaluates each patient
and help to determine eligibility. At many centers, pain
management, psychiatry, and nutritional expertise is also
utilized. We have recently employed laparoscopic pancreas
core biopsy as a minimally invasive procedure to establish a
histological diagnosis of pancreatitis in select patients where
the diagnosis is not firmly established.
Of note, there are no standardized patient selection guidelines endorsed by any of the major gastroenterology,
endocrinology, transplant, or surgical societies. However, a
consensus conference was held at Pancreasfest 2014, which
provided guidance statements around three areas in regard to
TP-IAT: (i) Indications and contraindications, (ii) Evaluation
and timing of the procedure, and (iii) Following patients after
TP-IAT.9 Pertinent recommendations of the committee are
shown in Table 1. Note however, that both the evidence level
and grade of recommendation for each guidance statement
were generally poor.
The major indications currently employed by United States
TP-IAT centers are discussed below. These apply only in
patients with confirmed diagnoses of CP, recurrent acute
pancreatitis (RAP), and/or hereditary pancreatitis.
Unresponsive to maximal medical and/or surgical
therapy. Before considering TP-IAT, all applicable lessinvasive therapies should be attempted. Depending on the
patient and the spectrum of disease, management using antioxidant supplementation, pancreatic enzyme replacement,
Clinical and Translational Gastroenterology

endoscopic decompression and/or stenting, celiac plexus
nerve block, and/or opiate regimens can sufficiently relieve
symptoms in some patients.11–16 Only after failure of these
therapies should TP-IAT be considered as TP-IAT is often
considered as a choice of last resort.
Techniques involving partial resection of the pancreas may
successfully treat pain, but should be evaluated with caution,
as loss of pancreatic tissue may reduce the islet yield and
negatively impact the success of a future TP-IAT.17 Like
resection procedures, decompressive procedures such as
pancreaticojejunostomy (Puestow) may also relieve pain, but
may negatively impact islet yield in those that subsequently
undergo TP-IAT.17,18
Metabolic status—adequate islet function. In addition to
exhausting alternative therapies, potential candidates for TPIAT should undergo metabolic assessment to validate islet
function. Patients must be non-diabetic or have C-peptide
positive diabetes to retain islet function following TP-IAT.9 So
far, attempts to reliably predict post-TP-IAT endocrine function have been unsuccessful, although studies have
observed positive correlations between greater islet cell yield
and insulin independence. Ahmad et al.17 reported that
insulin-independent TP-IAT patients received a significantly
higher mean islet yield (6,635 islet equivalents (IEQ)/kg)
compared with that of their insulin-dependent group (3,799
IEQ/kg, P = 0.04).17 Sutherland et al.19 observed a similar
trend, where 72% of patients receiving 45,000 IEq/kg were
insulin independent after 3 years, compared with only 22% in
a group that received 2,501–5,000 IEq/kg, and 12% in those
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receiving o2,500 IEq/kg. It should be noted that patients who
achieved only partial insulin independence, and thus still
benefited from auto-islet transplant, were not included in
these statistics. Other factors that have been shown to impact
islet yield and may warrant further investigation include
gender, alcoholic etiology, and pre-op insulin and C-peptide
responses.17,20,21
Quality of pain. The etiology of pain in pancreatitis is multifactorial and may originate from acinar necrosis, pseudocyst
formation, ductal hypertension, bile duct obstruction, and/or
neurogenic inflammation; as such, the presentations of pain
vary among patients.2,9 TP-IAT should be reserved only for
those patients with severe episodes of debilitative pain. From
an anecdotal perspective, we have seen a much better pain
response in patients with intermittent severe (type A) pain
rather than chronic daily (type B) pain.
Quality of life. TP-IAT is indicated only in those for whom the
post-operative sequelae cannot further diminish their Quality
of Life (QOL). This determination is particularly difficult to
make, because even mild pancreatitis will negatively impact
patients’ QOL.22,23 For this reason, it is recommended that
each patient be evaluated in this regard on a case-by-case
basis by a multidisciplinary TP-IAT team. Guidelines for
defining a severe QOL impairment would include loss of job,
inability to attend work or school, or frequent hospitalization.9
The SF-36 and SF-12 questionnaires can be useful both
pre- and post-TP-IAT to quantify patients’ QOL, and are
divided into a physical component summary and mental
component summary score. The mean score for healthy
individuals is 50, with a standard deviation of 10. Numerous
studies have used this scoring system to demonstrate QOL
improvement post-TP-IAT (Table 2).
CONTRAINDICTIONS FOR TP-IAT
Upon meeting the criteria indicating TP-IAT, the ideal
TP-IAT candidate must not have any of the following
contraindications:
Active substance abuse. Recent estimates indicate that
alcohol is the primary etiologic factor in 44–53% of CP cases
in the United States.24,25 It is the second most common factor
(after gallstones) in cases of acute pancreatitis, accounting
for roughly 36% of cases.26 Therefore, abstinence from
alcohol is often a first step in the management of pancreatitis,
as its consumption will worsen the condition by a variety of
mechanisms, regardless of the initial etiology.27
Table 2 Quality of life changes in recent TP-IAT series

Source

Patient

n

Survey

Baseline

1-Year

PCS MCS PCS MCS
Pediatric 19
Bellin et al.59
70
Sutherland et al.19 Adult
42
Adult
33
Morgan et al.

Sf-36
Sf-36
Sf-12

30
29
25

34
38
32

50
39
36

46
47
44

MCS, mental composite score; PCS, physical composite score; TP-IAT, Total
Pancreatectomy with Islet Autologous Transplant.

In addition, the rate of death among alcoholic CP patients is
nearly three times higher in those who continue to abuse
alcohol after their diagnosis (67 vs. 23%).28 Furthermore, it
has even been suggested that those with alcoholic pancreatitis may fare worse than others undergoing TP-IAT in
measures of QOL, islet yield, and insulin dependence.20
Thus, to maximize the benefit of TP-IAT, it is critical for the
patient to cease alcohol consumption. While no “required”
duration of abstinence to qualify for TP-IAT has been defined,
many centers have adopted 6 months as a standard based on
criteria for liver transplantation.9
Illicit drug use is contraindicated because it may contribute
to a patients’ inability to comply with or manage the complex
post-operative regimen. Additionally, drug-induced pancreatitis is a rare but genuine phenomenon, with poorly understood
toxicity mechanisms.29 While almost all cases reports of druginduced pancreatitis come from patients using prescription
medications, a few case reports have strongly linked heavy
cannabis use to the onset of acute pancreatitis.30,31
Pancreatic malignancy. Balzano et al.32 published an
international study of 34 patients in which TP-IAT was performed for reasons other than CP, calling for the expansion of
indications to include malignancy. Traditionally, this application has been avoided because islet isolation in the presence
of multifocal pancreatic cancers could lead to reintroduction
of malignant cells.32,33 Longitudinal research regarding the
recurrence rates of pancreatic cancers following autologous
islet transplant is lacking, and would be needed to safely
validate use of TP-IAT in cases of cancer. For this reason,
pancreatic cancer, as well as premalignant cystic disease
such as intraductal papillary mucinous neoplasm, remains an
absolute contraindication for TP-IAT.
Poorly controlled psychiatric illness. Following TP-IAT,
patients may require a complex regimen of enzyme therapy,
insulin dependence, and nutritional monitoring. Ensuring the
patient is mentally fit to manage the post surgical management process is critical for improving their QOL and health. A
strong support network often helps in this regard. The TP-IAT
team should take care not to overlook this criterion, as both
suicide and narcotic overdose have been reported postTP-IAT.17 At our center, psychiatric evaluation before TP-IAT
is mandatory for all patients.
Cost. Recently, Wilson et al.34 evaluated the cost effectiveness of TP-IAT in patients with minimal change CP, justifying
the substantial upfront costs of the procedure. It was found
that with TP-IAT, the total cost averaged $153,575 with a
survival of 14.9 quality adjusted life years. Comparatively,
medical management totaled $196,042 with a survival of
only 11.5 quality adjusted life years. However, despite the
lower cost and improved survival associated with TP-IAT,
many state entitlement programs do not reimburse for the
procedure. As such Medicare and Medicaid patients are
not accepted at many programs due to insufficient
reimbursement.
Clinical and Translational Gastroenterology
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Figure 1 Operative pancreatectomy. (a) Intra-operative identification of the splenic artery. (b) Mobilization of the pancreas and spleen. (c) Complete pancreatic explantation.

TP-IAT OPERATIVE PROCEDURE
Pancreatic resection and reconstruction. The pancreatectomy procedure will vary depending on the previous
surgical history of the patient and the condition of the
pancreas, as many patients will have undergone partial
resections before completion pancreatectomy. At our institution, we often begin laproscopically to establish pancreatic
mobilization, and convert to an open procedure for pancreas
explant. For those undergoing a complete total pancreatectomy, the surgical principal is to maintain arterial inflow and
venous outflow on the specimen during the dissection to
optimize islet perfusion and to avoid warm ischemia. This is
accomplished by preservation of the splenic artery and vein
and the gastroduodenal artery (GDA) during the resection.
Instead of dividing the neck of the pancreas attempts are
made to preserve the entire pancreas intact. This is facilitated
by developing the plane between the portal vein and the neck
of the pancreas to the right of the GDA. The “hanging
maneuver” can be employed to provide lateral traction on the
head during the uncinate dissection with preservation of the
GDA inflow by placing a quarter inch Penrose drain beneath
the neck bringing it up superior to the pancreas to the right of
the GDA. Once the entire specimen is mobilized from the
retroperitoneum and the bile duct, duodenum/stomach and
proximal jejunum are divided the splenic artery and vein and
GDA are ligated, divided and the specimen is passed off the
field for back table preparation (Figure 1).
Regarding reconstruction, a pylorus preserving pancreaticoduodenectomy is preferred to enable direct duodenal
anastomosis with the distal segment of duodenum. For
patients with significant duodenal resection, roux-en-y choledochojejunostomy or hepaticojejunostomy with gastrostomy is
often used alternatively.
Islet cell isolation. The explanted pancreas is placed
immediately into an ice-cold, antibiotic infused, static preservation solution (SPS-1) bath on ice. The splenic artery,
GDA, and pancreatic ducts are flushed with SPS-1. Next, the
intra-ductal distension method is used to initiate digestion; a
warm mixed enzyme solution of collagenase, buffers, and
proteases are infused directly into the cannulated pancreatic
duct. The parenchyma is then repeatedly injected with mixed
Clinical and Translational Gastroenterology

Figure 2 The pancreas explant after it has been infused with buffering solution
and is ready to undergo mechanical digestion.

enzyme solution under manual pressure generated by a 60
cc syringe to monitor the gland for optimal distension and
distribution of the enzyme solution throughout the parenchyma. Next, the gland is manually dissociated using scissors
to generate small 5-mm-sized chunks of tissue (Figure 2).
The entire collected tissue with enzyme solution is placed into
a Ricordi digestion chamber at 37 °C. The chamber is either
manually or mechanically “shaken” as it is brought to 37 °C to
initiate further mechanical dissociation and activate enzymatic digestion. Serial samples are taken every 5 min for
microscopy inspection to assess islet number, size, and
morphology using dithizone staining.
Upon completion of the digest, the Ricordi system is cooled
to 4 °C and the digest is collected for centrifugation. Human
serum albumin is added to the collection bottle to quench the
enzyme preparation, and a series of centrifugations and resuspensions with Hank’s balanced salt solution are used to
wash the islets. In cases where islet volume is large, a
purification step can be added to reduce the final volume, but
this may also reduce the final islet yield. The final pellet is then
suspended with 5% human serum albumin and 35 units of
Heparin per kilogram of patient body weight.

TP-IAT
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Islet cell infusion. Most centers infuse the islet cells via
catheter into the portal vein or mesenteric venous tributaries
for engraftment into the liver (Figure 3). Other sites, such
as the peritoneum, subcutaneous tissue and kidney capsule,
have been considered and are under investigation; however,
portal vein infusion has remained the gold standard to
date.35–37 To reduce complication rates of acute portal
hypertension and thrombosis, an endotoxin free, low-volume,
homogenous cell suspension is infused while the patient is
given intravenous heparin.38 We generally give the patient
35 U/kg intravenously and 35 U/kg of Heparin with the islets
during portal venous infusion; the patient receives a
therapeutic dose of 70 U/kg of heparin. Portal pressures are
closely monitored during infusion, as it has been recently
demonstrated that the risk of thrombosis increases tenfold

Figure 3 Islets being infused via arterial-line tubing into the superior
mesenteric vein.

(1.52–15.2%) in those with portal pressure changes greater
than 25 cm H2O.39
Operative risks. The reported complications and their frequencies within recently published TP-IAT series are displayed in Table 3. TP-IAT entails major surgery with risks that
may impede post-operative quality of life; i.e., in the largest
published series of TP-IAT procedures to date, 15.9% of
patients required reoperation.19 Major causes included bleeding (9.5%), anastomotic leak (4.2%), gastrointestinal distress
(4.7%), and intra-abdominal infection (1.9%).19 Furthermore,
following TP-IAT the patient will have complete pancreatic
exocrine insufficiency, necessitating life-long PERT.
PATIENT OUTCOMES
Pain. The primary goal of TP-IAT is to control the pain of CP
and prevent further episodes of pancreatitis in those with
RAP. When compared with other surgical management
techniques such as pancreaticoduodenectomy, distal pancreatectomy, or pancreaticojejunostomy, TP-IAT has demonstrated excellent outcomes in regard to pain relief (Table 4).
Still, depending on the center performing the surgery, an estimated 10–20% of TP-IAT patients will not achieve significant
long-term pain control.9,40 Moreover, a small subset of patients
will report their pain has worsened following TP-IAT; Sutherland et al.19 reported this finding in 3–6% of their cohort.
A useful metric in evaluating pain relief is the post-operative
reduction in opiate use. Nearly, all TP-IAT patients are chronic
opiate users pre-operatively, and there is wide variation in use
depending on the patient population and the duration of their
pancreatitis. For example, a recent study by Wilson et al.41
found that before operation, their pediatric cohort averaged
32.7 mean morphine equivalents per day. In comparison,
Morgan et al.42 published results from an adult cohort where
patients averaged 357 mean morphine equivalents per day.

Table 3 Post-operative complications in recent TP-IAT series

Series

n

Ahmad et al.17

45

Delayed gastric emptying (4)
Deep vein thrombosis (4)
Pulmonary embolism (3)
Urinary tract infection (3)
Central line infection (3)
Death (3a)

Intra-abdominal hematoma (3)
Pneumonia (1)
Intra-abdominal abscess (1)
Pneumothorax (1)
Neuropraxia (1)

Morgan et al.42

33

Pneumonia (6)
Wound infection (4)
Urinary tract infection (3)
Intra-abdominal abscess (2)
Deep vein thrombosis (2)
Sepsis (1)

Respiratory failure (1)
Acute renal failure (1)
Biliary stricture (1)
Hepatic artery pseudoaneurysm (1)
Portal vein thrombosis (1)

Sutton et al.43 (Pediatric)

16

Pneumonia (3)
Delayed gastric emptying (1)

Wilson et al.41 (Pediatric)

14

Acute respiratory distress (1)
Pneumonia (1)
Urinary tract infection (1)

Complications reported (n)

[Central line associated] bacteremia (1)

TP-IAT, Total Pancreatectomy with Islet Autologous Transplant.
a
1 Hepatic failure, 1 narcotic overdose, and 1 suicide.

Clinical and Translational Gastroenterology
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Table 4 Pain relief following pancreatic resection

Source

Procedure
60

Jimenez et al.

61

Hutchins et al.
Bradley62

Beger et al.63
Sutherland et al.19

Standard pancreaticoduodenectomy
Pylorus-preserving pancreaticoduodenectomy
Distal pancreatectomy
Lateral pancreaticojejunostomy
Caudal pancreaticojejunostomy
Duodenum-preserving pancreatic head resection
TP-IAT

n

% Achieving pain relief (complete+partial)

33
39
84
42
18
479
207

70
60
57
66
34
91
94

TP-IAT, Total Pancreatectomy with Islet Autologous Transplant.

Table 5 Daily morphine equivalents (ME) pre-TP-IAT and narcotic use post-TP-IAT

Source

Year

n

Patient type

Pre-TP-IAT mean ME

Sutherland et al.19
Ahmad et al.17
Morgan et al.42
Walsh et al.45
Rilo et al.46
Sutton et al.43
Wilson et al.41
Chinnakolta et al.44

2012
2005
2012
2012
2003
2010
2013
2014

207
45
33
20
22
16
14
75

Mixed
Mixed
Adult
Adult
Adult
Genetic CP
Pediatric
Pediatric

N/A
206
357
89.2
78.4
185
32.7
N/A

Post-TP-IAT % narcotic free
46% at 1 year
58% at last follow-up
23% at 1 year
30% at last follow-up
82% at last follow-up
63% at last follow-up
79% at 6 months
480% at 1 year

CP, chronic pancreatitis; TP-IAT, Total Pancreatectomy with Islet Autologous Transplant.

Fortunately, for nearly all patients, this level of intensive
narcotic use will decrease post-TP-IAT, with 23–82% achieving complete independence9,19,41–46 (Table 5). For some
patients, the inability to fully wean from narcotics has been
attributed to opiate-induced hyperalgesia, neurological central
sensitization, gastrointestinal dysmotility, and/or chronic post
surgical pain.9,19 Factors that have been found to positively
correlate with narcotic independence include lower preoperative use and preadolescence (age o13).17,47 However, a
multicenter, prospectively designed modeling tool has never
been constructed to pinpoint the patient and disease
characteristics that predict the most favorable and negative
outcomes.
Endocrine function. With regard to endocrine functionality,
it is estimated that following autologous islet transplant, about
one-third of patients become insulin free and one-third will
have partial islet function, requiring only minimal insulin. The
remaining third will require standard daily insulin, and about
10% of islet transplants will result in complete graft failure,
potentially leaving the patient with unstable type 3c
diabetes.21,48 The unstable “brittle” diabetic state can be
especially detrimental to the patient, predisposing them to
episodes of wide glycemic excursions and ketoacidosis.
Additionally, the long-term durability of beta cell function
remains uncertain. In the University of Minnesota series,
among patients who initially achieved insulin independence,
nearly half (46%) were no longer independent after 5 years.19
Within this group, higher rates of independence correlated
positively with the quantity of islets per kilogram transplanted.
Of those with partial post-operative graft function, many
regressed to a state of complete dependence over time
(58% had partial function at 6 months, while only 33% have
partial function at 3 years).19
Clinical and Translational Gastroenterology

FUTURE DIRECTIONS
Predictive modeling. Currently, there is no predictive model
to determine which patients will have a successful short- or
long-term outcome following TP-IAT. While there have been
recommendations from Pancreasfest and single institutions,
a prospectively derived model needs to be developed.9,49 In
addition, validated shared decision making aids could prove
to be invaluable resources for patients in succinctly outlining
the risks and benefits of the procedure.
“Remote” TP-IAT isolation. “Remote TP-IAT Isolation”
refers to the concept of performing the TP-IAT with collaboration from two sites; one to perform the pancreatectomy,
and another to perform the islet cell isolation. This enables
centers not equipped with islet isolation facilities to offer TPIAT to their patients, but comes with several potential drawbacks. Most importantly, it requires that two surgeries be
conducted instead of one, greatly increasing total procedure
length, sometimes to more than 24 h. Not only is this
challenging to coordinate, but the additional transit time is
associated with longer periods of cold ischemia and thus
potentially a decrease in islet viability.50,51 Finally, outsourcing the islet isolation is an expensive endeavor due to
transportation and laboratory fees in the realm of $50,000.
Intra-operative isolation. In an effort to reduce the reliance
of TP-IAT on an FDA-approved isolation facility, several
centers have begun performing islet cells intra-operatively.
The advantage to this method is that costs are considerably
lower per isolation and there is a not the need to maintain an
FDA-approved alloislet facility. Comparative effectiveness
studies in regard to islet yields and patient outcomes have
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yet to be performed comparing standard and intra-operative
isolation.
Investigational therapeutics to maximize islet yield
Interleukin-8 receptor inhibition. It is believed that intraportal
micro-thrombosis or transient ischemia following islet infusion
may contribute significantly to graft loss due to the secretion
of tissue factor by the islet cells in response to the clotting
reaction.52 This process has been termed instant blood
mediated inflammatory injury, and has been estimated to
account for the loss of up to 60–80% of transplanted islets.53
The drug Reparixin, an Interleukin-8 (CXCL8) receptor
inhibitor, is currently in phase III clinical trials and targets
this inflammatory pathway to improve islet engraftment. In
its recent phase II trial, patients receiving allogenic islet
transplants with Reparixin demonstrated significantly higher
C-peptide levels, higher islet estimated function, and lower
insulin requirements compared with the control group.54
Glucagon-like peptide 1 analogs. Glucagon-like peptide 1
(GLP-1) analogs have been pursued for many years as
adjuvant therapy to boost transplanted islet function. It is
hypothesized that the denervation of islets during the isolation procedure is responsible for a reduced response to
incretins like GLP-1, and that exposure to GLP-1 analogs
early in transplant therapy may improve function in islet
transplant recipients.55 Specifically, Exenatide, an inhibitor of
Dipeptidyl peptidase 4, acts to prevent degradation of GLP-1
and has been shown to stimulate insulin secretion, protect
beta cells from apoptotic mechanisms, and even promote
beta cell regeneration; it has thus been proposed as a
adjunctive pre-treatment in islet cell transplantation and is still
under investigation.56
Non-hepatic sites of implantation
The peritoneum. It has been previously suggested that
recipients of intrahepatic islet transplant do not respond to
hypoglycemia with adequate glucagon secretion by alpha cells,
placing recipients at risk for severe hypoglycemia unawareness.57 Perhaps, the most accepted theory that could explain a
subpar alpha response is that hypoglycemia-induced glycogen
breakdown increases glucose locally within the liver, and thus
could negate systemic signals of hypoglycemia to alpha cells
residing in the hepatic parenchyma. However, recent work by
these groups has also shown intra-hepatic alpha cells to
respond sufficiently to intravenous arginine stimulation, calling
the functionality of alpha cells post-TP-IAT into question.58
In light of this issue, the peritoneum is currently under
investigation as a promising secondary transplant site for islet
recipients. Bellin et al.59 found that in patients in whom a
portion of islets were transplanted into the peritoneal cavity,
acute glucagon responses to arginine stimulation were comparable to those of a normal control, whereas the response
was completely absent in patients that received only intrahepatic transplant.
CONCLUSION
Although first performed in 1977, it is only in the last decade
that TP-IAT has gained worldwide attention and adoption as a
therapy for painful CP. Despite very promising results in certain

series, it is a drastic intervention that should only be considered in highly selected patients. While progress has been
made to refine operative technique, islet manipulation and
patient identification, there is still much progress to be made.
Currently, many patients are rendered insulin dependent
following TP-IAT and up to 15% have no improvement in their
pain. This is a procedure for patients who have few other
options, and who must be prepared to trade one disease
(chronic pain) for potentially another (diabetes).
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ The pain of chronic pancreatitis is often difficult to manage.
✓ TP-IAT has been performed since 1977 to treat the pain of
chronic pancreatitis.

WHAT IS NEW HERE
✓ TP-IAT is increasingly being performed in the United States.
✓ In hightly selected patients, pain relief is excellent.
✓ More research into optimal patient selection is necessary.
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